Nanjing Leads Biolabs (HKG:9887) said its investigational cancer therapy LBL-024 received approval from China's National Medical Products Administration to begin clinical trials for the treatment of metastatic colorectal cancer, according to a Monday Hong Kong bourse filing.
The approval covers a Phase 1b/2 study evaluating LBL-024, a PD-L1/4-1BB bispecific antibody, in combination therapy for metastatic colorectal cancer.